HR+/HER2- advanced breast cancer
Oct 23, 2018
Notizia
Novartis comes up with an answer for breast cancer with PI3K drug alpelisib Novartis comes up with an answer with its recent data on BYL719 (alpelisib) in combination with fulvestrant. Their alpha-specific drug for PIK3CA mutated HR+/HER2- advanced breast cancer, BYL719 plus fulvestrant nearly doubled the progressio...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
